Serial EntrepreneurAbout
General Biotechnologies manufactures peptide therapeutics at a fraction of the current cost by genetically programming edible microbes to synthesise complex molecules. The company uses a programmable edible microbe (UTEX 3222) found in volcanic seeps to produce oral peptide drugs delivered in an edible powder format.
Traction & Metrics
Financial
$0
MRR
Fundraising
$4.5M
Previous Round
Products
Regenesis™ Oral Peptide Platform
Next-generation oral peptide therapeutics delivered in an edible powder format. Uses genetically engineered UTEX 3222 microbe (Cyanobacterium aponinum 'Chronus') as a drug-delivery capsule that protects 90% of peptides through the stomach. The microbe's thick cell wall and acid-resistant properties enable oral delivery of peptides that normally require injection, reducing costs by 42-84% compared to traditional manufacturing. Platform enables production of GLP-1, BPC-157, and other peptides at $2.90-$5.00 per day retail price.
Click to read more
Oral GLP-1
Regenesis GLP-1 200mg PO (once daily)
Updates
General Bio raises $7m (2025)
https://www.axios.com/pro/biotech-deals/2026/07/20/general-bio-7-million-oral-peptides